139 related articles for article (PubMed ID: 38543281)
1. Validated LC-MS/MS Assay for the Quantitative Determination of Fenretinide in Plasma and Tumor and Its Application in a Pharmacokinetic Study in Mice of a Novel Oral Nanoformulation of Fenretinide.
Matteo C; Orienti I; Eramo A; Zeuner A; Ferrari M; Passoni A; Bagnati R; Ponzo M; Bello E; Zucchetti M; Frapolli R
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543281
[TBL] [Abstract][Full Text] [Related]
2. A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells.
Orienti I; Salvati V; Sette G; Zucchetti M; Bongiorno-Borbone L; Peschiaroli A; Zolla L; Francescangeli F; Ferrari M; Matteo C; Bello E; Di Virgilio A; Falchi M; De Angelis ML; Baiocchi M; Melino G; De Maria R; Zeuner A; Eramo A
J Exp Clin Cancer Res; 2019 Aug; 38(1):373. PubMed ID: 31439019
[TBL] [Abstract][Full Text] [Related]
3. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
Cooper JP; Reynolds CP; Cho H; Kang MH
Exp Biol Med (Maywood); 2017 Jun; 242(11):1178-1184. PubMed ID: 28429653
[TBL] [Abstract][Full Text] [Related]
4. Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics.
Cho HE; Min HK
J Pharm Biomed Anal; 2017 Jan; 132():117-124. PubMed ID: 27701038
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide.
Formelli F; Cavadini E; Luksch R; Garaventa A; Villani MG; Appierto V; Persiani S
Cancer Chemother Pharmacol; 2008 Sep; 62(4):655-65. PubMed ID: 18066548
[TBL] [Abstract][Full Text] [Related]
6. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
Maurer BJ; Kalous O; Yesair DW; Wu X; Janeba J; Maldonado V; Khankaldyyan V; Frgala T; Sun BC; McKee RT; Burgess SW; Shaw WA; Reynolds CP
Clin Cancer Res; 2007 May; 13(10):3079-86. PubMed ID: 17505011
[TBL] [Abstract][Full Text] [Related]
7. A rapid, sensitive and selective liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry method for determination of fenretinide (4-HPR) in plasma.
Lee JI; Nguyen VT; Chen ML; Adamson PC
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Feb; 862(1-2):64-71. PubMed ID: 18032119
[TBL] [Abstract][Full Text] [Related]
8. P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.
Lopez-Barcons L; Maurer BJ; Kang MH; Reynolds CP
Int J Cancer; 2017 Jul; 141(2):405-413. PubMed ID: 28340497
[TBL] [Abstract][Full Text] [Related]
9. Enhanced anti-neuroblastoma activity of a fenretinide complexed form after intravenous administration.
Carosio R; Pistoia V; Orienti I; Formelli F; Cavadini E; Mangraviti S; Montaldo PG; Ognio E; Emionite L; Zuccari G
J Pharm Pharmacol; 2012 Feb; 64(2):228-36. PubMed ID: 22221098
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines.
Kalemkerian GP; Slusher R; Ramalingam S; Gadgeel S; Mabry M
J Natl Cancer Inst; 1995 Nov; 87(22):1674-80. PubMed ID: 7473815
[TBL] [Abstract][Full Text] [Related]
11. Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies.
Awosemo O; Neelakantan H; Watowich S; Ma J; Wu L; Chow DS; Liang D
J Pharm Biomed Anal; 2021 Sep; 204():114255. PubMed ID: 34304009
[TBL] [Abstract][Full Text] [Related]
12. Attempts to Improve Lipophilic Drugs' Solubility and Bioavailability: A Focus on Fenretinide.
Alfei S; Zuccari G
Pharmaceutics; 2024 Apr; 16(5):. PubMed ID: 38794242
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.
Poliakov E; Samuel W; Duncan T; Gutierrez DB; Mata NL; Redmond TM
PLoS One; 2017; 12(4):e0176487. PubMed ID: 28448568
[TBL] [Abstract][Full Text] [Related]
14. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
[TBL] [Abstract][Full Text] [Related]
15. Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients.
Formelli F; Cavadini E; Luksch R; Garaventa A; Appierto V; Persiani S
Cancer Chemother Pharmacol; 2010 Oct; 66(5):993-8. PubMed ID: 20532509
[TBL] [Abstract][Full Text] [Related]
16. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl)retinamide] sufficient for cancer therapy?
Ohlmann CH; Jung C; Jaques G
Int J Cancer; 2002 Aug; 100(5):520-6. PubMed ID: 12124800
[TBL] [Abstract][Full Text] [Related]
17. Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1.
Villani MG; Appierto V; Cavadini E; Valsecchi M; Sonnino S; Curley RW; Formelli F
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6265-75. PubMed ID: 15448016
[TBL] [Abstract][Full Text] [Related]
18. Fenretinide-polyethylene glycol (PEG) conjugate with improved solubility enhanced cytotoxicity to cancer cell and potent
Wang Y; Ding Y; Wang C; Gao M; Xu Y; Ma X; Ma X; Cui H; Li L
Pharm Dev Technol; 2020 Oct; 25(8):962-970. PubMed ID: 32366203
[TBL] [Abstract][Full Text] [Related]
19. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators.
Batra S; Reynolds CP; Maurer BJ
Cancer Res; 2004 Aug; 64(15):5415-24. PubMed ID: 15289350
[TBL] [Abstract][Full Text] [Related]
20. HPLC-MS/MS method for quantitative determination of the novel dual inhibitor of FGF and VEGF receptors E-3810 in tumor tissues from xenograft mice and human biopsies.
Zangarini M; Ceriani L; Bello E; Damia G; Cereda R; Camboni MG; Zucchetti M
J Mass Spectrom; 2014 Jan; 49(1):19-26. PubMed ID: 24446259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
